


PHARMACEUTICAL 2022

Savara Inc Rank 157 of 475







PHARMACEUTICAL 2022

Savara Inc Rank 157 of 475



The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savara Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 158% points. The greatest weakness of Savara Inc is the variable Revenues, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is -17%, being 260% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	165,000
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,660
Liabilities, Non-Current	17,440
Other Assets	11,525
Other Compr. Net Income	-937
Other Expenses	136
Other Liabilities	0
Other Net Income	-1,537
Property and Equipment	73
Research and Development	28,991
Revenues	0
Selling, General and Administrative Expense	12,350

Output Variable	Value in 1000 USD
Assets	176,598
Liabilities	32,100
Expenses	41,477
Stockholders Equity	144,498
Net Income	-43,014
Comprehensive Net Income	-43,482
Economic Capital Ratio	-17%

